Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BACKGROUND: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of progressiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghen, Charlien, Joniau, Steven, Rans, Kato, Devos, Gaëtan, Poels, Kenneth, Slabbaert, Koen, Dumez, Herlinde, Albersen, Maarten, Goffin, Karolien, Haustermans, Karin, De Meerleer, Gert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245754/
https://www.ncbi.nlm.nih.gov/pubmed/32448171
http://dx.doi.org/10.1186/s12885-020-06853-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245754/
https://www.ncbi.nlm.nih.gov/pubmed/32448171
http://dx.doi.org/10.1186/s12885-020-06853-x

Ejemplares similares